

EU Generic Market Overview

EU Generic Market Overview.....	19
Generics.....	19
Generics and Cost-Saving.....	20
The Generics Industry in Europe – A Brief	21
Price Regulationa and Cost Containment – Effect on generics	25
Market Overview.....	27
Characteristics of the European Generics Industry.....	30
Market Drivers	31
Market Restraints	33
REGULATORY ISSUES	35
Marketing Authorization Procedure for Generic Drugs: Three Authorization Procedures	35
<i>The Centralized Procedure</i>	<i>35</i>
<i>The Decentralized Procedure.....</i>	<i>36</i>
SmPCs: a Major Hurdle	37
Contested applications	38
"Biosimilar" applications	38
Bolar provisions.....	39
Generic Substitution	40
IPR Issues in Europe	40
Table of Contents	
Patents	40
<i>Ever increasing patent protection</i>	<i>40</i>
<i>Strategic 41</i>	
<i>Risk of I42</i>	
<i>Further Protection</i>	<i>42</i>
<i>Generics do not use originator data</i>	<i>43</i>
Data Exclusivity is not Data Protection	43
<i>Current legal framework</i>	<i>44</i>
<i>New legal framework - Harmonization of the data exclusivity period and addition of new periods of data exclusivity</i>	<i>44</i>
<i>Data Excludi44</i>	
Evergreening through Patent Strategies	45
<i>Evergreening and Pharmaceutical Research Costs</i>	<i>46</i>
<i>"Life-cycle management" and Evergreening</i>	<i>47</i>
<i>Questionable practices - higher prices for patients</i>	<i>48</i>
EU ENLARGEMENT	48